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ABSTRACT: 
Seventeen adult male and female subjects participated in a clinical trial using an open-label 
trial to evaluate the effectiveness of pyrroloquinoline quinone (PQQ) on stress, fatigue, quality 
of life and sleep. They ingested 20 mg of PQQ daily for 8 weeks. Changes in stress, fatigue, 
quality  of  life  measures  and  sleep  were  evaluated  using  various  inventories  and 
questionnaires. For example, the results of the Profile of Mood States-Short Form revealed that 
all six measures of vigor, fatigue, tension-anxiety, depression, anger-hostility and confusion 
were significantly improved following PQQ administration compared with scores for those 
measures  before  administration  of  PQQ.    Measures  for  quality  of  life,  appetite,  sleep, 
obsession and pain, also improved significantly. The results of the Oguri-Shirakawa-Azumi 
Sleep  Inventory  (Middle  Aged  and  Aged  version)  showed  significant  improvement  in 
sleepiness at awakening, sleep onset and maintenance, and sleep duration. For validation, the 
Pittsburgh Sleep Quality Index Japanese version also  showed significant improvement in 
sleep-related behavior. Furthermore, the changes in these global scores were correlated with Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 308 of 324 
changes  in  the  cortisol  awakening  response  (R  =  -0.55),  i.e.  the  effects  of  PQQ  on 
improvement of sleep quality are supported by a biomarker. 
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INTRODUCTION: 
Pyrroloquinoline quinone (PQQ) is an organic molecule discovered in bacteria in 1979 as the 
third redox coenzyme following nicotinamides (pyridine nucleotides) and flavines  PQQ  is 
water-soluble, having 3 carboxyl groups, a quinone, and chemical properties similar to the 
combined attributes of ascorbic acid, riboflavin, and vitamin B6. PQQ is present in various 
vegetables and beverages, especially in tea, natto (fermented soybeans), and fruits [1, 2], and is 
also found in the human tissues and fluids, especially breast milk. In animal studies, PQQ as 
administration  influences  anti-oxidative  capacity,  nerve  growth  factor  enhancement  and 
mitochondrial biogenesis [3-7]. Based on such data, we conducted studies that indicate PQQ 
administration has a positive influence on brain functions, especially short-term memory and 
attention  in  elderly  healthy  volunteers  [8].  Accordingly,  and  to  add  to  our  previous 
observations, we focus herein on mental stress, fatigue, quality of life (QOL) and sleep quality. 
Adult male and female office workers who complained of fatigue and/or disordered sleep were 
used as subjects. 
 
SUBJECTS AND METHODS: 
Test substance. The test substance was provided in the form of a hard capsule containing 20 
mg  of  pyrroloquinoline  quinone  Na2  salt  (BioPQQ
TM)  manufactured  by  Mitsubishi  Gas 
Chemical Co., Inc. (Tokyo, Japan). A capsule was ingested with a cup of water once a day after 
breakfast. The time of ingestion and the number of capsules ingested were recorded in a diary. 
The duration of the study was 8 weeks. The dose of 20 mg of PQQ per day was based on our 
previous clinical study [8].   
 
Study  design.  The  study  followed  an  open-label  trial.    The effectiveness  of PQQ  was 
assessed by comparing the evaluation measures before and after PQQ administration. Primary 
evaluations consisted of four methods of subjective self-reporting were adopted for evaluating 
stress, fatigue, QOL and sleep quality. In addition, the increase of cortisol secretion called the 
cortisol awakening response (CAR) was measured. We adopted CAR as an objective method 
of  evaluation.  In  general,  job  stress  or  general  life  stress  raises  the  cortisol  following Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 309 of 324 
awakening, while fatigue, burnout or exhaustion reduces that [9]. With respect to sleep, some 
studies report that high CAR is associated with healthy sleep [10, 11] 
 
Subjects.  Seventeen volunteers were selected from adult male and female workers with  a 
diagnosed  sleep  disorder  or  complaint and fatigue using as  selection criteria  the Athens 
Insomnia Scale (AIS), a scale of insomnia [12], and the Profile of Mood States-Short Form 
(POMS-S) [13] . 
Selection criteria were: (1) men and women aged from 20 to 60; (2) those employed 
full-time; (3) those who scored over 6 points on the AIS at the examination before enrollment; 
and (4) those who scored over 50 points in the T score of fatigue and below 50 points in the T 
score of vigor  on the POMS-S at  the examination before enrollment.  Exclusion  criteria, 
discontinuance  criteria,  dropout  criteria,  and  restrictions  were  listed  in  Supporting 
Information.   
The study was conducted in compliance with the “Declaration of Helsinki” and “The 
Ethical Guideline for Epidemiological Study” (issued in 2004 by the Ministry of Education, 
Culture, Sports, Science and Technology, and the Ministry of Health, Labour and Welfare). 
The study (Protocol No.21584) was approved by the clinical study review committee of the 
Miho Clinic (Tokyo, Japan) on the basis of the protocol and information on the test substance 
on July 17, 2009. Actual study was done in Ueno Clinic (Tokyo, Japan). The details of this 
study were explained to the subjects before the start of the study and informed consent given by 
free will was obtained from each subject. 
 
Study timelines. The subjects visited Ueno Clinic for the first examination. Prior to PQQ 
intervention, the subjects filled out the POMS-S inventory, the life event survey, the Pittsburgh 
Sleep Quality Index Japanese version (PSQI-J) and the QOL questionnaire and underwent 
physical examination (anthropometry, blood pressure and heart rate) and blood and urine tests. 
Following selections, subjects were next kept overnight in a comfortable setting so that saliva 
samples could be collected 30 min after awakening to determine the cortisol levels in saliva.  
The subjects then filled out the Oguri-Shirahata-Azumi Sleep Inventory (Middle Aged and 
Aged version) (OSA-MA) soon after awakening to evaluate sleep quality during the past one 
week. 
The subjects were then instructed to ingest the test substance and visit the clinic on the 
weekends  of the 1st  (1w), 2nd (2w), 4th  (4w) and 8th  week (8w) after the  initiation  of 
supplementation. On the clinic examination days, they filled out the QOL questionnaire every 
4 weeks and the POMS-S every 2 weeks. The POMS-S on the 6th weekend (6w) was filled out Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 310 of 324 
at home. An examination of their general condition, including physical examination as well as 
blood and urine tests, was conducted every 4 weeks. On weekend days, the OSA-MA was 
filled out soon after awakening at home. Saliva samples were collected soon after and 30 min 
after awakening on the latest weekday before the clinic examination day of the weekends of 4w 
and 8w. On the examination day, the collected saliva samples were brought to the clinic. The 
test schedule is shown in Table S1 (see Supporting Information). The duration of this study 
was from July to November, 2009. 
 
Evaluation  of  POMS-S  and  QOL.  The  effectiveness  of  PQQ  was  evaluated  using  the 
POMS-S and the QOL Questionnaire to measure the changes at each time point after ingestion 
and also by the results of intergroup comparison between the values prior to supplementation 
(the baseline values) and the values at each time point after supplementation. 
The  POMS  Japanese  version  is  a  questionnaire  comprising  65  questions  about  six 
components: tension-anxiety, depression, anger-hostility, vigor, fatigue and confusion [14]. 
The POMS-S shortens the number of questions from 65 to 30, for ease of use [13]. Despite 
this, it is highly reliable and produces similar results to the POMS. For each question, the 
subjects select one of five answers ranging from “not at all” (0 points) to “very frequently” (4 
points), according to how many times the mood in question occurred in the past 7 days. All 30 
questions are divided into six components with five questions each, and the total points for 
each component are calculated and designated the raw score. After the raw score is corrected 
for age and gender, the standardized score (T score) is calculated. The higher score for vigor 
indicates the better condition, while the lower score for the other five components indicates the 
better condition. 
QOL was evaluated by Nagata’s QOL Questionnaire [15,  16], scoring measures  for 
appetite,  sleep,  excretion,  urination,  exercise,  obsession,  pain,  sexual  life,  social  life, 
happiness, family life, and fullness and satisfaction in the overall daily life. For each question, 
the subjects select one of five to twelve answers ranging from “best” (1 points) to “worst” (5 
points). In cases of multiple answers, the maximum point score was adapted. For all measures, 
the lower score indicates the better condition. 
 
Evaluation of sleep. Two subjective methods were employed to enhance the reliability of the 
results of evaluation: the OSA Sleep Inventory and the PSQI-J, which measured changes at 
respective examination time points after the start of the ingestion of PQQ, allowing intergroup 
comparison between the values before ingestion (baseline values) and those after ingestion. Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 311 of 324 
The OSA-MA consists of 16 questions divided into five factors: Factor I (sleepiness at 
awakening),  Factor  II  (sleep  onset  and  maintenance),  Factor  III  (nightmare),  Factor  IV 
(recovery from fatigue) and Factor V (sleep duration)[17]. The subjects select, soon after 
awakening in the morning, the best answer to each question from the following: “remarkably”, 
“modestly”, “slightly” and “not at all”. The answers are converted into Zc  points and the 
average point score for each factor is calculated as the evaluation score of that factor (Factor I: 
0-32.3, Factor II: 0-29.6, Factor  III: 0-29.5, Factor IV: 0-32.7, Factor V: 0-33.5). For all 
questions, the higher score means the better condition. 
The PSQI is a questionnaire developed in the US for screening of sleep disturbance, 
composed  of  18  questions for the  seven components of sleep quality, sleep latency, sleep 
duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication and daytime 
dysfunction. In this study, the PSQI-J was used [18-20]. The PSQI global score (from 0 to 21) 
was obtained by totaling the scores of the seven components (0–3). Higher global scores show 
more disturbed sleep, with a total score of more than six indicating sleep disturbance. The 
global score and the scores of the seven components were calculated. 
 
Measurement of salivary cortisol. In the present study, the increase of salivary cortisol level 
from soon after awakening to 30 min after awakening was defined as CAR  and  used to 
determine the amount of cortisol secretion non-invasively [9]. 
Samples were collected on the latest weekday before the examination day and on the 
examination day (weekend) at 0w (before PQQ ingestion), 4w and at 8w by using the saliva 
sampling tube (Salisoft) (Assist Co., Tokyo, Japan). The times of awakening and sample 
collection were recorded. Until the completion of sample collection, eating, drinking, smoking 
and tooth brushing were not permitted. The saliva samples collected were kept in a home 
refrigerator and brought in a cooler bag with cooling agent to the clinic on examination day. 
The concentration of salivary cortisol was determined by means of the salivary cortisol EIA kit 
(Salimetrics) of expanded range and high sensitivity. 
 
Safety evaluation. Adverse events were recorded for subjects who had taken PQQ at least 
once. Any undesirable subjective or objective symptom was regarded as an adverse event and 
appropriate treatment was administered if necessary, with recording of details of symptoms 
and findings, the date of occurrence and the date of resolution. The seriousness of the event, the 
details of treatment (if treated), the outcome and the cause and effect relationship to PQQ were 
reviewed and recorded on the case report form. Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 312 of 324 
The safety of PQQ was evaluated based on the adverse events (subjective symptoms, 
objective findings and abnormal changes in the measured values) that were judged to be 
possibly related to PQQ.   
 
Statistical analysis. All measured values and changes were expressed as mean ± SD. If the 
analysis of variance by repeated measure revealed a statistically significant difference in the 
measured value before and after ingestion, the baseline value and the measured values at each 
examination time after ingestion were compared by the single sample t-test for the POMS-S 
and OSA-MA. For PSQI-J and QOL, the values were compared by the Wilcoxon signed rank 
test.  The  multiple  comparisons  were  made  by  the  Holm’s  method.  For  the  physical 
examination values, the changes at each time point after ingestion from the baseline values 
were evaluated by the single sample t-test. The two-sided level of significance was 5%. 
 
RESULTS: 
Subjects: background information and physical examination. 
The seventeen subjects (seven men and ten women) were 38.1±7.4 years old. The results of 
physical examination are presented in Table 1. There was no discontinuance or dropout during 
the study period. At the time of their selection, the scale for sleeplessness by the AIS was 
12.6±2.8 and the global score by the PSQI-J was 10.0±1.9, demonstrating disordered sleep. 
The T score of [Vitality] in the POMS-S was 35.7±4.6 and that of [Fatigue] was 71.8±5.1, 
demonstrating stress and fatigue. During the study, none of the subjects had any major changes 
in employment and working hours or stressful events such as changes in home environment, 
diseases and birth or death of close relatives. 
 
Table 1. Results of physical examination 
 
Measurement  Unit  0w  4w  8w 
Height  cm  163.75±9.47     
Weight  kg  58.26±10.33  58.35±10.39  58.66±10.60 
BMI  kg/m
2  21.54±1.93  21.58±1.93  21.68±2.03 
Systolic blood pressure  mmHg  112.5±12.2  108.6±11.4 *  113.0±11.1 
Diastolic blood pressure  mmHg  66.8±7.2  65.5±6.1  67.6±4.3 
Heart Rate  bpm  70.1±7.2  68.1±10.1  66.9±6.8 
n = 17 paired t-test *：  p < 0.05 Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 313 of 324 
Effects of PQQ on stress, fatigue and QOL. 
The results of POMS-S to evaluate stress and fatigue are presented in Figure 1. The analysis of 
variance by repeated measures revealed that duration-dependent significant decreases were 
observed in five components, except vigor, with PQQ ingestion. 
The scores of mood states before PQQ ingestion and after eight-weeks of PQQ ingestion 
are shown in Figure 2. After 8w, the T score of vigor increased, while those of other five 
components decreased. These results indicated improvements in stress and fatigue with PQQ. 
The results of the evaluation of QOL  are shown in Table 2. The  four measures of 
(Appetite,  Sleep,  Obsession  and  Pain)  significantly  declined,  indicating  significant 
improvement with PQQ. The three measures of (Fullness of social life, Happiness and fullness 
in the family life, and Fullness and satisfaction in the overall daily life) showed tended to 
decline (i.e. improve). 
 
 
Figure 1. Effects of PQQ supplementation on POMS-S scores of (A) Tension-Anxiety, (B) Depression, 
(C) Anger-Hostility, (D) Vigor, (E) Fatigue, and (F) Confusion (n = 17). Vertical bars indicate standard 
deviation. (paired t-test **：p < 0.01, *：p < 0.05)   
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Figure 2. Effects of PQQ supplementation on POMS-S scores (n = 17).  Vertical  bars  indicate  standard 
deviation. (paired t-test **：p < 0.01, *：p < 0.05).  
         
Table 2. Effects of PQQ supplementation on QOL scores 
 
Measurement      0w      4w      8w 
Appetite  3.5±0.9  2.5±0.9 **  2.3±0.7 ** 
Sleep  4.2±0.4  3.5±0.9 *  3.0±0.9 ** 
Excretion  3.0±0.8  2.9±0.9  2.6±1.1 
Urination  3.4±0.9  2.8±1.1  2.9±0.8 
Exercise  3.4±1.3  3.6±1.1  3.6±1.0 
Obsession  3.8±0.8  3.2±1.3 *  2.5±1.1 ** 
Pain  3.6±0.8  3.3±0.8 *  2.9±1.1 * 
Sexual life  3.8±1.0  3.6±1.2  3.6±1.2 
Fullness of the patient's social life  3.0±0.7  2.6±0.6  2.5±0.5 
Happiness and fullness in family life  2.4±1.1  2.2±0.9  2.0±1.0 
Fulfillment and satisfaction in overall 
daily life 
3.1±0.4  2.8±0.6  2.7±0.6 
 
n = 17, Wilcoxon signed rank test (multiple comparison by Holm's test)   
**：p < 0.01, *：p < 0.05 
 
Effects of PQQ on sleep. 
The  results  of  the  OSA-MA  are  shown  in  Figure  3.  PQQ  ingestion  caused  significant 
duration-dependent improvements in four of the five factors except for Factor III (nightmare). Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 315 of 324 
Table 3 shows the results of the PSQI-J. The PSQI-J global score went down depending 
on the duration of PQQ ingestion, as did individual components such as sleep quality, sleep 
latency, sleep duration and daytime dysfunction. 
Finally, to investigate the relation of CAR to sleep, the correlation between CAR and the 
global score of PSQI-J was assessed. The ten subjects with CAR values below zero at 0w and 
8w were excluded as “non-compliant to protocol”,  i.e.  collection  of  saliva  beyond  the  30 
minutes post-sleep cut-off [9, 21, 22] (Table S2, see Supporting Information). In the analyses 
of seven compliant subjects, the 8-week changes in PSQI scores were correlated with changes 
in CAR (R = -0.55) (Figure 4). 
 
Table 3. Effects of PQQ supplementation on sleep (PSQI-J scores) 
 
Component  0w  4w  8w 
PSQI-J global score  10.0±1.9  8.2±2.1 **  6.4±2.0 ** 
Sleep quality  2.2±0.4  1.6±0.5 **  1.5±0.7 ** 
Sleep latency  2.1±0.9  1.8±0.8  1.4±0.9 ** 
Sleep duration  2.4±0.6  2.1±0.6 *  1.9±0.6 ** 
Habitual sleep efficiency  0.5±0.6  0.2±0.4  0.1±0.2 
Sleep disturbance  1.1±0.3  1.1±0.7  0.8±0.6 
Use of sleeping medication  0.0±0.0  0.2±0.7  0.0±0.0 
Daytime dysfunction  1.8±0.8  1.4±0.5 *  0.9±0.7 ** 
n = 17, Wilcoxon signed rank test (multiple comparison by Holm's test)**：p < 0.01, *：p < 0.05 
 
Safety. 
1.  Subjective symptoms and objective symptoms 
During ingestion of PQQ, six events occurred in five subjects, but were not judged as related to 
PQQ. These events  were  the  common cold  in four subjects  including  one  complaint  of 
abdominal  pain  and  a  slight fever in another  subject. Symptoms were minor and transient 
despite continued ingestion of PQQ. 
2.  Results of physical examination 
Table 1 shows the changes of mean values and standard deviations obtained from the physical 
examination. They were judged that all of the changes were clinically negligible.    There were 
no adverse events. Systolic blood pressure was also reduced significantly at 4w, a clinically 
significant positive effect. Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 316 of 324 
 
Figure  3.  Effects  of  PQQ  supplementation  on  OSA-MA  scores  of  (A)  Factor  I 
(sleepiness at  awakening), (B)  Factor II (sleep onset and maintenance), (C) Factor III 
(nightmare), (D) Factor IV (recovery from fatigue), and (E) Factor V (sleep duration) (n = 
17).Vertical bars indicate standard deviation. (paired t-test **：p < 0.01, *：p < 0.05).   
 
 
Figure 4. The correlation between changes in weekday CAR and changes in PSQI-J global 
score after 8 weeks of ingestion (n = 7). The line represents a linear regression (y = -0.27 x 
-3.57, R = -0.55). Raw data represents Table S4. Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 317 of 324 
DISCUSSION: 
This was the first human study on the effectiveness of oral PQQ supplementation focusing on 
stress, fatigue, sleep and QOL.  Both the OSA-MA and PSQI-J demonstrated significantly 
improved sleep quality. The concurrent results from two different evaluation methods strongly 
supported study validity. The results of subjective evaluations by the POMS-S, OSA-MA and 
PSQI-J suggest that PQQ supplementation also improved sleep, leading to reduced negative 
mental states, relief of fatigue and rise of positive mood (Table 2). 
The scores of the five components, except vigor, in the POMS-S evaluation continued to 
fall and scores for vigor continued to rise during 8 weeks (Figure 1). Scores of most factors of 
the OSA-MA showed an upward trend during 8 weeks (Figure 3). These data suggest that PQQ 
improved not only fatigue but also disordered sleep and QOL. 
To examine the physiological basis of this action, we also measured CAR as a biomarker. 
It  has  been reported that  sleep quality is  closely related to  CAR  [11].  Moreover,  in the 
comparison between primary insomnia patients and healthy volunteers, Backhaus et al. [10] 
observed that the average cortisol level of the former at awakening was significantly lower 
than that of the latter. On the other hand, lower PSQI-J global score indicates better sleep 
quality. In the analysis of our compliant subjects (n = 7), a correlation was observed between 
changes in PSQI-J global score and changes in CAR after 8-weeks of PQQ ingestion (Figure 4 
and Table S3, see Supporting Information). These findings suggest that when normal sleep is 
recovered with PQQ and cortisol secretion due to sleep disturbance is repressed, which occurs 
with a normal or improved awakening response.   
This study is the first human clinical trial on the effect of PQQ on stress, fatigue, and 
sleep,  to  better  reflect  the  primary  outcome  measurements.  The  results  of  this  trial  are 
therefore, encouraging and should be extended in a placebo-controlled study with a larger 
study population. The anti-oxidative capacity or mitochondrial biogenesis function of PQQ 
might be responsible for the outcomes in this study. However, the elucidation of the mode of 
action is needed in further study. 
 
Conclusions:  In conclusion, PQQ supplementation seems associated with improved sleep 
quality  and  duration.    Mood  also  was  improved  by  diminishing  feelings  of  fatigue,  and 
improved QOL on measures of appetite, sleep, pain and obsession. The improvement of the 
PSQI-J global score correlated with changes in CAR. These data indicate that PQQ can be 
regarded as a potentially useful dietary supplement as it may relate to improving fatigue.   
Importantly, no health issues were associated with PQQ supplementation. 
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Supporting Information 
 
Subjects and Methods 
Exclusion criteria 
1) Those who took routinely the foods or health foods compounded with the active 
constituent of this test food (PQQ) 
2) Those who had regularly any medical treatment (or corresponding treatment) or took 
medicines or health foods for the purpose of improving sleep, fatigue and stress 
3) Those who were engaged to works on a day-night shift or physical labors such as 
transportation of heavy goods and were working on an irregular schedule 
4) Those  who  did  not  follow  the  prescribed  procedures  for  various  examinations 
performed  during  this  study  (such  as  saliva  sampling  soon  after  awakening  or  filling  in 
questionnaires) 
5) Those who had diseases under treatment or to be treated, including insomnia 
6) Those who had the anamnesis of serious diseases such as diabetes mellitus, hepatic 
disorders,  renal  disorders,  hypertension,  cardiovascular  disorders  and  abnormal  glucose 
tolerance 
7) Those who were judged inadequate as the subject from the results of laboratory tests 
and physical examination performed before ingestion 
8) Those who might possibly show allergic reaction to the test food (PQQ or other 
ingredients) 
9) Those who expected to become pregnant during the study and were pregnant or 
breast-feeding 
10) Those who had been already enrolled in another clinical study when they were 
recruited to this study 
11) Those who were judged inadequate as the substance by the principal investigator of 
this study 
 
Discontinuance criteria 
The principal investigator could discontinue the study for the subject, when the principal 
investigator judged that the subject in question fell under the following items, and it was 
treated as a discontinuance case. 
1) When the subject might threaten the safety of other subjects 
2) When it was difficult to continue this study due to occurrence of any serious clinical 
abnormality or accident Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 322 of 324 
3) When any critical or continuous deviation from the protocol was found during the 
study   
4) When the principal investigator decided to discontinue this study 
 
Dropout criteria 
When the subject withdrew from the study due to the personal reason or intention after the 
subject had agreed to enroll in this study, the principal investigator discontinued soon this 
study for the subject in question and treated it as a dropout case. 
 
Restrictions   
During the study, every subject had to comply with the following restrictions (including the 
notices to be followed till the day before examination and those on the day of examination). 
1) The lifestyle before the enrollment in this study (eating, drinking, exercise, sleep, 
smoking, etc.) should be almost kept during the study.    Excessive exercise, drinking and 
eating should be avoided. 
2) When any medicine was taken, its name and amount should be recorded on the 
diary. 
3) The test food should be taken every day in the prescribed amount. 
4) The diary should be kept every day. 
5) The measures to relieve stress should be taken within the ordinary range. 
6) On  the  day  before  examination,  alcohol  should  not  be  taken,  and  hard  exercise 
should be avoided.   
7) On the day before visiting the clinical for examination, eating and drinking should be 
prohibited after 24 o’clock, except drinking water or tepid water. 
8) On the day of examination, the subjects should take the prescribed breakfast and 
thereafter should fast to the end of examination (water or tepid water is accessible). 
9) The subjects should fill in the OSA-MA and collect the saliva sample before the time 
limit soon after awakening on the appointed day for examination.    On the day of saliva 
sampling, eating, drinking, smoking and tooth brushing should not be permitted before the 
finish of saliva sampling 30 min after awakening. 
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Table S1. Test schedule and test item 
               T e s t   s c h e d u l e  
 
Test item 
Before 
ingestion 
Duration of ingestion 
*1 *2 1w 2w 3w 4w 5w 6w 7w 8w
Hospital visiting (holiday)    ●  ●  ●  ●      ● 
Selection of subjects    ●          
Lifestyle questionnaire  ●           
AIS  ●           
Physical examination    ●  ●  ●  ●      ● 
Blood and urine tests    ●          
Sleep 
OSA-MA    ●  ●  ●  ●  ●  ●  ●  ●  ● 
PSQI-J    ●      ●      ● 
CAR    ●      ●      ● 
Stress 
Fatigue 
POMS  ●  ●  ●  ●  ●  ● 
Life-event survey  ●  ●  ●  ●  ●  ●  ● 
QOL questionnaire    ●  ●  ●  ●      ● 
Ingestion of test substance       
Record in a diary     
*
1: Pre-enrollment examination 
*
2: Pre-ingestion examination Functional Foods in Health and Disease 2012, 2(8):307-324                                                  Page 324 of 324 
Table S2. Effects of PQQ supplementation on salivary cortisol at awakening and CAR 
in compliant seven subjects (per protocol base) (Mean ± SD) 
Measurement Unit  0w 4w  8w 
Weekday 
at awakening  nmol/l  8.9 ± 4.3  11.4 ± 5.4  10.4 ± 5.8 
30 min after awakening  nmol/l  14.7 ± 7.2 #  13.7 ± 7.0  16.7 ± 8.3 # 
CAR nmol/l  5.8 ± 4.7  2.3 ± 8.7  6.3 ± 4.8 
Weekend 
at awakening  nmol/l  11.5 ± 4.7  9.9 ± 5.0  10.6 ± 6.6 
30 min after awakening  nmol/l  17.4 ± 9.1 #  11.9 ± 7.9  16.9 ± 8.9 # 
CAR nmol/l  5.9 ± 5.0  1.9 ± 5.8  6.3 ± 4.6 
Significant difference between salivary cortisol at awakening and salivary cortisol 30 
min after awakening (paired t-test)    #: p < 0.05. 
 
Table S3. Raw data of Figure 4 
  Weekday CAR (nmol/l)  PSQI-J global score 
Subject No.  0w  8w  ⊿CAR  0w 8w  ⊿PSQI-J global score 
1 0.2  8.1  7.9  7  3  -4 
2 13.1  4.8  -8.3  9  8  -1 
3 5.0  8.1  3.1  11  4  -7 
4 8.2  1.0  -7.2  10  9  -1 
5 9.6  14.6  5.0  13  4  -9 
6 1.5  6.9  5.4  9  8  -1 
7 2.8  0.7  -2.1  10  7  -3 
 